NCT02115750

Brief Summary

This is a two part study comparing CHS-0214 to Enbrel in patients with active rheumatoid arthritis and an inadequate response with Methotrexate (MTX) who are naive to biologic therapies. Pt.1 is a 24-week randomized, double-blind, active-control, parallel-group, multi-center global study. The primary end point is 20% improvement in American College of Rheumatology criteria (ACR-20) at week 24. Comparing CHS-0214 to Enbrel for efficacy and safety. Pt. 2 is an open-label single arm study in which patients with at least an ACR-20 response receive CHS-0214. Continued response and safety will be evaluated.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
647

participants targeted

Target at P75+ for phase_3 rheumatoid-arthritis

Timeline
Completed

Started May 2014

Geographic Reach
12 countries

141 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 14, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 16, 2014

Completed
15 days until next milestone

Study Start

First participant enrolled

May 1, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2016

Completed
3.2 years until next milestone

Results Posted

Study results publicly available

June 26, 2019

Completed
Last Updated

June 26, 2019

Status Verified

June 1, 2019

Enrollment Period

1.4 years

First QC Date

April 14, 2014

Results QC Date

December 18, 2018

Last Update Submit

June 7, 2019

Conditions

Keywords

CHS-0214EnbrelRABiosimilarEtanercept

Outcome Measures

Primary Outcomes (1)

  • ACR-20 - 20% Improvement According to American College of Rheumatology Criteria

    The primary efficacy endpoint in Part 1 was the percentage of subjects who achieved ACR20 (20% improvement according to American College of Rheumatology criteria) at week 24 compared to baseline (last non-missing value prior to first dose). Subjects were considered an ACR20 responder if when compared to baseline (last non-missing value prior to first dose), they achieved a 20% decrease in SJC (Swollen joint count), 20% decrease in TJC (Tender joint count), and 20% improvement in 3 of the following 5 measures: high sensitivity C reactive protein(hs-CRP), Health Assessment Questionnaire Disability Index(HAQ-DI), subjects global assessment of pain(SPA, VAS), subject's global assessment of disease activity(SGA-VAS), physician's global assessment of disease activity(PGA-VAS)

    24-weeks

Secondary Outcomes (6)

  • ACR20 - (20% Improvement According to American College of Rheumatology Criteria) at Weeks 4, 8, 12, and 18

    Weeks 4, 8, 12 and 18

  • Summary of Change in Tender Joint Count (TJC) by Study Visit

    Weeks 4,8,12,18,24,28,36,48

  • Summary of Change in Swollen Joint Count (SJC) by Study Visit

    Weeks 4,8,12,18,24,28,36,48

  • Summary of Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) by Study Visit

    Weeks 4,8,12,18,24,28,36,48

  • Summary of Change in Subject's Pain Assessment - Visual Analog Scale (SPA-VAS) by Study Visit

    Weeks 4,8,12,18,24,28,36,48

  • +1 more secondary outcomes

Study Arms (2)

Enbrel (etanercept)

ACTIVE COMPARATOR

Enbrel 50mg weekly times 24 weeks.

Drug: Etanercept

CHS-0214

EXPERIMENTAL

CHS-0214 50mg weekly times 24 weeks.

Drug: CHS-0214

Interventions

Head-to-head comparison

Also known as: Enbrel, European Enbrel
Enbrel (etanercept)
CHS-0214

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or female adults
  • RA (Rheumatoid Arthritis) diagnosis for 6 months
  • On stable dose of MTX of 8mg to 25mg per week
  • Active disease: greater than 6 tender joints, greater than 6 swollen joints, C-reactive protein (CRP) greater than or equal to 0.5mg/dL, and disease activity score (DAS) with 28 joints (DAS28-CRP(4)) greater than or equal to 3.2

You may not qualify if:

  • Use of prednisone greater than 10mg/day
  • Use of greater than one non-steroidal anti-inflammatory drug (NSAID)
  • Use of biologic therapies for any cause
  • Chemistry and hematology values outside protocol specified range
  • Positive QuantiFERON-tuberculosis (TB) Gold Test
  • Evidence of active lung disease on chest x-ray
  • Major systemic infections
  • Presence of significant comorbid conditions
  • Known allergy to latex
  • Women who are pregnant or nursing

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (141)

Elite Clinical Studies

Phoenix, Arizona, 85018, United States

Location

Arizona Research Center

Phoenix, Arizona, 85020, United States

Location

NEA Baptist Clinic

Jonesboro, Arkansas, 72401, United States

Location

Dream Team Clinical Research

Anaheim, California, 92801, United States

Location

Advanced Medical Research

Lakewood, California, 90712, United States

Location

Pro Health Partners

Long Beach, California, 90808, United States

Location

St. Joseph Hospital of Orange

Orange, California, 92868, United States

Location

Desert Medical Advances

Palm Desert, California, 92260, United States

Location

Kaiser Permanente - CA

Richmond, California, 94801, United States

Location

Med Investigators, Inc

Roseville, California, 95661, United States

Location

Troum Medical Associates

Santa Monica, California, 90404, United States

Location

Inland Rheumatology Clinical Trials Inc

Upland, California, 91786, United States

Location

IMMUNOe International Research Centers

Centennial, Colorado, 80112, United States

Location

Hope Clinical Research

Kissimmee, Florida, 34741, United States

Location

Advanced Medical Research, Inc

Orlando, Florida, 32804, United States

Location

Allergy & Rheumatology Associates LLC

St. Petersburg, Florida, 33708, United States

Location

HealthPoint Medical Group

Tampa, Florida, 33614, United States

Location

Bluegrass Community Research, Inc

Lexington, Kentucky, 40504, United States

Location

The Center for Rheumatology and Bone Research

Wheaton, Maryland, 20902, United States

Location

Clinical Pharmacology Study Group

Worcester, Massachusetts, 01605, United States

Location

St. Louis Center for Clinical Research

St Louis, Missouri, 63128, United States

Location

Arthritis Center of Nebraska

Lincoln, Nebraska, 68516, United States

Location

Pacific Arthritis Center Medical Group

Omaha, Nebraska, 68198, United States

Location

Rheumatoid Arthritis Investigational Network

Omaha, Nebraska, 68198, United States

Location

North Shore University Hospital

Great Neck, New York, 11021, United States

Location

Montefiore Medical Center

The Bronx, New York, 10467, United States

Location

DJL Clinical Research

Charlotte, North Carolina, 28210, United States

Location

PMG Research of Wilmington LLC

Wilmington, North Carolina, 28401, United States

Location

Altoona Center for Clinical Research

Duncansville, Pennsylvania, 16635, United States

Location

Low Country Rheumatology

Charleston, South Carolina, 29406, United States

Location

Arthritis Clinic

Jackson, Tennessee, 38305, United States

Location

Texas Physicians Medical Research Group

Arlington, Texas, 76015, United States

Location

Metroplex Clinical Research Center

Dallas, Texas, 75231, United States

Location

Pioneer Research Solutions Inc

Houston, Texas, 77036, United States

Location

Arthritis Northwest Rheumatology PLLC

Spokane, Washington, 99204, United States

Location

Rheumatic Disease Center

Glendale, Wisconsin, 53217, United States

Location

Gundersen Lutheran Medical Center

Onalaska, Wisconsin, 54650, United States

Location

Brest Regional Clinical Hospital

Brest, 224027, Belarus

Location

Grodno Regional Clinical Hospital

Grodno, 230017, Belarus

Location

Gomel Regional Clinical Hospital

Homyel, 246029, Belarus

Location

City Clinical Hospital #1 - Belarus

Minsk, 220013, Belarus

Location

City Clinical Hospital #9 - Belarus

Minsk, 220116, Belarus

Location

Vitebsk Regional Clinical Hospital

Vitebsk, 210037, Belarus

Location

Hôpital Michallon - CHU de Grenobl

Grenoble, 38434, France

Location

CHU Bicetre

Le Kremlin-Bicêtre, 94275, France

Location

Centre Hospitalier Regional D'Orleans

Orléans, 45067, France

Location

Hopital Cochin-Saint Vincent de Paul

Paris, 75014, France

Location

Hopital de Saint Etienne

Saint-Etienne, 42055, France

Location

Asklepios Klinikum Bad Abbach

Bad Abbach, 93077, Germany

Location

Klinische Forschung Dresden GmbH

Dresden, 01069, Germany

Location

Center of Innovative Diagnostics and Therapeutics Rheumatology/Immunology

Frankfurt, 60528, Germany

Location

Universitätsmedizin Göttingen

Göttingen, 37075, Germany

Location

SMO.MD GmbH - Zentrum fuer klinische Studien

Magdeburg, 39112, Germany

Location

St. Rokus Hospital, BAJA

Baja, 6500, Hungary

Location

DRC Gyogzszervizsgalo Kozpont

Balatonfüred, 8230, Hungary

Location

Orszagos Reumatologiai es Fizioterapias Intezet

Budapest, 1023, Hungary

Location

Qualiclinic Kft

Budapest, 1036, Hungary

Location

Békés Megyei Pándy Kálmán Kórház

Gyula, 5700, Hungary

Location

University of Szeged, Faculty of Medicine

Szeged, 6725, Hungary

Location

Rakoczi Ferenc Korhaz-CRU Hungary (KFT)

Szikszó, 3800, Hungary

Location

Rambam Medical Center

Haifa, 3109601, Israel

Location

Tel Aviv Sourasky Medical Center

Tel Aviv, 64239, Israel

Location

Sheba Medical Center

Tel Litwinsky, 52621, Israel

Location

Assaf Harofeh Medical Center

Ẕerifin, 70300, Israel

Location

Nagoya University Hospital

Nagoya, Aichi-ken, 466-8560, Japan

Location

Inoue Hospital

Takasaki-shi, Gunma, 370-0053, Japan

Location

Hiroshima Clinic

Nishiku, Hiroshimashi, 733-0032, Japan

Location

Izumi Himawari Clinica

Sendai, Miyagi, 981-3135, Japan

Location

Miyashita Rheumatology Clinic

Omura-shi, Nagasaki, 856-0836, Japan

Location

Japanese Red Cross Okayama Hospital

Okayama, Okayama-ken, 700-8607, Japan

Location

Japanese Red Cross Nagoya Daiichi Hospital

Aichi, 453-8511, Japan

Location

Yamada Rheumatology Clinic

Ehime, 790-0905, Japan

Location

University of Occupational and Environmental Health Hospital

Fukuoka, 807-8556, Japan

Location

Kondo Clinic for Rheumatism and Orthopaedics

Fukuoka, 810-0001, Japan

Location

Medical Co. LTA PS Clinic

Fukuoka, 812-0025, Japan

Location

Shono Rheumatism Clinic

Fukuoka, 814-002, Japan

Location

St Mary;s Hospital

Fukuoka, 830-8543, Japan

Location

Hiroshima Rheumatology Clinic

Hiroshima, 730-0017, Japan

Location

Medical Corporation Nakayama Clinic

Hyōgo, 650-0044, Japan

Location

Matsubara Mayflower Hospital

Hyōgo, 673-1462, Japan

Location

Eiraku Clinic

Kagoshima, 890-0055, Japan

Location

Izumihara Rheumatic and Medical Clinic

Kagoshima, 890-0067, Japan

Location

Kawasaki Rheumatism and Internal Medicine Clinic

Kanagawa, 212-0014, Japan

Location

Kumamoto Orthopaedic Hospital

Kumamoto, 862-0976, Japan

Location

Munakata Yasuhiko Clinic

Miyagi, 980-6166, Japan

Location

Yu-Family Clinic

Miyagi, 981-0112, Japan

Location

Sendai Taihaku Hospital

Miyagi, 982-0032, Japan

Location

Kai Clinic

Miyazaki, 880-0053, Japan

Location

Zenjinkai Shimin no Mori Hospital

Miyazaki, 880-0122, Japan

Location

Komagamine Orthopaedic Rheumatic Clinic

Morioka Iwate, 020-0034, Japan

Location

Nagasaki Medical Hospital of Rheumatology

Nagasaki, 850-0832, Japan

Location

Nagasaki University Hospital

Nagasaki, 852-8501, Japan

Location

SaSebo Chuo Hospital

Nagasaki, 857-1195, Japan

Location

Yoshida Orthopaedic and Rheumatology Clinic

Numakunai, 020-0015, Japan

Location

Rinku Hashimoto Rheumatology Orthopedics

Osaka, 598-0048, Japan

Location

Oribe Clinic of Rheumatism and Medicine

Ōita, 870-0823, Japan

Location

Otsuka Clinica of Rheumatism and Medicine

Ōita, 870-1155, Japan

Location

Koshigaya Municipal Hospital

Saitama, 343-8577, Japan

Location

Medical Corporation Kojyokai Hirose Clinic

Saitama, 359-1111, Japan

Location

Hokkaido Medical Center for Rheumatic Diseases

Sapporo, 063-0811, Japan

Location

St. Luke's International Hospital

Tokyo, 104-8560, Japan

Location

Keio University Hospital

Tokyo, 160-8582, Japan

Location

Miyasato Clinic

Yamaguchi, 745-0824, Japan

Location

Tokito Clinic Rheumatology and Orthopaedics, Surgery

Yamaguchi, 752-0976, Japan

Location

Centrum Kliniczno Badawcze

Elblag, 82-300, Poland

Location

Synexus Polska Sp. z o.o. Oddzial w Gdyni

Gdynia, 81-384, Poland

Location

Mazowieckie Centrum Badan Klinicznych (MCBK) SC

Grodzisk Mazowiecki, 05825, Poland

Location

Synexus Polska Sp. z o.o. Oddzial w Katowicach

Katowice, 40-040, Poland

Location

Centrum Terapii Wspólczesne

Kodz, 90242, Poland

Location

NZOZ Lecznica MAK-MED

Nadarzyn, 05-830, Poland

Location

Profmedicus sp. z o.o

Olsztyn, 10696, Poland

Location

Centrum Medyczne SYNEXUS Poznan

Poznan, 60702, Poland

Location

Prywatna Praktyka Lekarska Prof UM dr hab. Med. Pawel Hrycaj

Poznan, 61-639, Poland

Location

Synexus Polska Sp. z o.o. Oddzial w Warszawie

Warsaw, 01-192, Poland

Location

Centrum Medyczne AMED

Warsaw, 01518, Poland

Location

Biogenes NZOZ

Wroclaw, 53-224, Poland

Location

Synexus Polska Sp. z o.o

Wroclaw, 53-413, Poland

Location

Krasnoyarsk Medical Academy

Krasnoyarsk, 660022, Russia

Location

State Healthcare Institution of Moscow City Clinical Hospital #15 n.a. O.M. Filatov

Moscow, 111539, Russia

Location

Practicheskaya Meditsina, Ltd

Moscow, 115404, Russia

Location

Republican Hospital n.a. V.A. Baranov

Petrozavodsk, 185019, Russia

Location

Medical Research Institute, LLC

Saint Petersburg, 196084, Russia

Location

St. Petersburg State Healthcare Institution "Consultative diagnostic center #85

Saint Petersburg, 198260, Russia

Location

Smolensk State Medical University (SSMU)

Smolensk, 214019, Russia

Location

Municipal Healthcare Institution "Emergency Clinical Hospital n.a. N.V. Soloviev

Yaroslavl, 150003, Russia

Location

Sverdlovsk Regional Clinical Hospital #1

Yekaterinburg, 620102, Russia

Location

MBI "Central City Clinical Hospital #6

Yekaterinburg, 620149, Russia

Location

Dr CI Louw

Cape Town, 7500, South Africa

Location

Dr S Nayiager

Durban, 4001, South Africa

Location

Wits Donald Gordon Clinical Trial Site

Johannesburg, 2193, South Africa

Location

Drs Dindar and Partners

Mpumalanga, 2330, South Africa

Location

Private Practice - Cathy Spargo

Pinelands, 7405, South Africa

Location

Jakaranda Hospital Pretoria

Pretoria, 0002, South Africa

Location

Emmed Research

Pretoria, 0084, South Africa

Location

Winelands Rheumatology Centre

Stellenbosch, 7600, South Africa

Location

Hospital Universitario Ramon y Cajal

Madrid, 28034, Spain

Location

Hospital La Paz

Madrid, 28046, Spain

Location

Hospital Regional Universitario de Málaga

Málaga, 29009, Spain

Location

Royal Sussex County Hospital

Brighton, BN25PE, United Kingdom

Location

Harrogate District NHS Foundation Trust

Harrogate, HG27SX, United Kingdom

Location

Wirral University Teaching Hospital NHS Foundation Trust

Merseyside, CH495PE, United Kingdom

Location

MeSH Terms

Conditions

Arthritis, Rheumatoid

Interventions

Etanercept

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesConnective Tissue DiseasesSkin and Connective Tissue DiseasesAutoimmune DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Immunoglobulin Fc FragmentsImmunoglobulin FragmentsPeptide FragmentsPeptidesAmino Acids, Peptides, and ProteinsImmunoglobulin Constant RegionsImmunoglobulinsImmunoproteinsBlood ProteinsProteinsSerum GlobulinsGlobulinsReceptors, Tumor Necrosis FactorReceptors, CytokineReceptors, ImmunologicReceptors, Cell SurfaceMembrane Proteins

Results Point of Contact

Title
Barbara K. Finck, MD Chief Medical Officer
Organization
Coherus BioSciences, Inc

Study Officials

  • Barbara K Finck, M.D.

    Coherus Oncology, Inc.

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 14, 2014

First Posted

April 16, 2014

Study Start

May 1, 2014

Primary Completion

October 1, 2015

Study Completion

May 1, 2016

Last Updated

June 26, 2019

Results First Posted

June 26, 2019

Record last verified: 2019-06

Locations